FIASP FLEXTOUCH
FIASP FLEXTOUCH (insulin aspart) is a rapid-acting human insulin analog. It is indicated to improve glycemic control in both adult and pediatric patients with diabetes mellitus. This medication serves as a therapeutic intervention for managing blood sugar levels in these patient populations.
How FIASP FLEXTOUCH Works
This drug regulates glucose metabolism by stimulating peripheral glucose uptake, particularly in skeletal muscle and fat. It further lowers blood glucose levels by inhibiting the production of glucose in the liver. Additionally, the medication inhibits the breakdown of fats and proteins while enhancing protein synthesis.
Details
- Status
- Prescription
- First Approved
- 2017-09-29
- Routes
- SUBCUTANEOUS
- Dosage Forms
- SOLUTION
FIASP FLEXTOUCH Approval History
What FIASP FLEXTOUCH Treats
1 indicationsFIASP FLEXTOUCH is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Diabetes
Drugs Similar to FIASP FLEXTOUCH
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
FIASP FLEXTOUCH FDA Label Details
ProIndications & Usage
FDA Label (PDF)NOVOLOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. NOVOLOG is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus .
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.